Why the study?
Does the change in serum soluble ST2 levels predict subsequent mortality or transplantation in patients with severe chronic NYHA class III to IV heart failure?
Population
Patients with severe chronic NYHA class III to IV heart failure
Design
Cohort
Authors
Loading...
ST2 changes may refine prognosis in advanced HF; hypothesis-generating and should not yet alter management.
Does the change in serum soluble ST2 levels predict subsequent mortality or transplantation in patients with severe chronic NYHA class III to IV heart failure?
Serum soluble ST2 is identified as a novel biomarker whose changes independently predict mortality or transplantation in severe heart failure.
Weinberg et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: